Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 277

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 7
Chunk 277
---
Cash Flows 

Comparison of the Years Ended December 31, 2024 and 2023

The following table details the primary sources and uses of cash for each of the periods set forth below: 

    Year Ended December 31,

    2024

    2023

    (in thousands)

    Net cash (used in) provided by:

    Operating activities
     
    $
    (68,717
    )
     
    $
    (192,977
    )

    Investing activities

    8,624

    123,866

    Financing activities

    59,282

    2,010

    Net decrease in cash, cash equivalents and restricted cash
     
    $
    (811
    )
     
    $
    (67,101
    )

93

Operating activities 

Net cash used in operating activities was $68.7 million in 2024 as compared to $193.0 million in 2023. The decrease of $124.3 million was primarily due to lower cash operating expenses in 2024 as compared to 2023, primarily due to lower compensation-related costs resulting from lower headcount driven by November 2023 and January 2024 reductions in force, as well as the $40.0 million received from Pierre Fabre in 2023 for development milestones met in December 2022, with no similar cash flows received in 2024. 

Investing activities 

Net cash provided by investing activities in 2024 consisted of $28.5 million received from maturities and sales of available-for-sale securities, partially offset by $19.7 million used to purchase available-for-sale securities and $0.2 million in purchases of property and equipment. 

Net cash provided by investing activities in 2023 consisted primarily of $208.7 million received from maturities and sales of available-for-sale securities, partially offset by $83.6 million used to purchase available-for-sale securities and $1.2 million in purchases of property and equipment. 

Financing activities

Net cash provided by financing activities in 2024 consisted primarily of $50.6 million of net proceeds from sale of common stock and pre-funded warrants in registered direct offerings, and $9.3 million of net proceeds from ATM facilities. 

Net cash provided by financing activities in 2023 consisted primarily of $2.1 million of net proceeds from ATM facilities and $0.9 million of net proceeds from employee stock award transactions.